Viking Global’s Top 5 Stocks

4. BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Percentage of Viking Global’s 13F Portfolio: 3.46%

Viking Global’s Stake Value: $1,247,726,000

Number of Hedge Fund Holders: 28

BridgeBio Pharma, Inc. (NASDAQ:BBIO), a California-based biotech company, is one of the top stocks sitting in Viking Global’s portfolio since the second quarter of 2019. In Q3 2021, Viking Global held the largest stake in the company, worth $1.25 billion.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) markets two FDA-approved rare genetic disease therapies namely Nulibry and Truseltiq. In addition, the biopharmaceutical firm is working on 30 gene therapy pipelines that could potentially treat muscle dystrophies, cardiorenal syndromes, and cancer. 

As per Insider Monkey’s Q3 data, the number of hedge funds holding stakes in BridgeBio Pharma, Inc. (NASDAQ:BBIO) stood at 28 in Q3, compared with 27 in the previous quarter. 

In the Q2 2021 investor letter, Baron Opportunity Fund highlighted a few stocks, and Bridgebio Pharma Inc. (NASDAQ:BBIO) is one of them. Here is what the fund said:

“BridgeBio Pharma, Inc. is a biotechnology company developing drugs that address a host of genetic disorders. Shares fell in the quarter given concerns around increasing competition. While we expect positive results from BridgeBio’s Phase 3 trial for its lead program for TTR amyloidosis, a disease in which toxic proteins build up in the heart and nerves, encouraging updates from Alnylam’s competing drug, Vitrusiran, and more recently, Intellia’s gene editing platform, pressured the stock. We exited our position.”